Growth hormone secretion regulator

Inactive Publication Date: 2009-02-19
AJINOMOTO CO INC
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0023]The present invention provides an agent for preventing or ameliorating deterioration of health conditions due to an age-related reduction in growth hormone secretion such as a decrease in the secreted amount of a growth hormone and a change in the secretion pattern. Specifically, the present invention provides: a growth hormone secretion regulator which regulates the secreted amount of a growth

Problems solved by technology

As a result, the above-mentioned effects are reduced, resulting in causing symptoms of aging (Non-patent Document 1).
However, these conventional arts are technologies developed in disregard of a pulsed secretion pattern of a growth hormone.
Conventional administr

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Growth hormone secretion regulator
  • Growth hormone secretion regulator
  • Growth hormone secretion regulator

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0072]

[0073]The growth hormone secretion regulating function of amino acids to be used in the present invention was evaluated by investigating changes in growth hormone secretion caused by intravenous administration of amino acid solutions. The details are as follows.

[0074]Special grade aspartic acid (Ajinomoto Co., Inc.) and valine (Ajinomoto Co., Inc.) were used as L-type amino acid samples. The amino acids were dissolved in purified water or an aqueous solution of 5% carboxymethylcellulose and administered as aqueous solutions (pH 7.0 to 8.0).

[0075]Two- to four-year-old mature castrated male and female shiba-goats (25 to 35 kg), purchased from the farm of Tokyo University, were domesticated for about one week. Aspartic acid (0.75 mmol / kg), valine (1.0 mmol / kg), and a mixture thereof, prepared in the same way as above, were administered intravenously via a cannula placed in the jugular vein, and blood was collected continuously during a period between 6 hours before and 12 hours a...

example 2

[0078]

[0079]Two- to four-year-old mature castrated male and female shiba-goats (25 to 35 kg), purchased from the farm of Tokyo University, were domesticated for about one week. Sodium aspartate monohydrate (5 mmol / kg, 861 mg / kg), valine (5 mmol / kg, 586 mg / kg), and a mixture thereof, prepared in the same way as Example 1, were administered orally to the shiba-goats, and blood was collected continuously during a period between 6 hours before and 12 hours after administration every 15 minutes via a cannula placed in the jugular vein, followed by investigation of changes in growth hormone secretion (n=3). The concentrations of the growth hormone in blood were measured by immunoassay in which europium was used.

[0080]The growth hormone and antibody used in the immunoassay were purchased from National institute of Diabetes and Digestive and Kidney Diseases. The other procedures were performed based on a reference (Sugino T et al., Biochemical and biophysical research communications 295: 25...

example 3

[0082]

[0083]Diabetes and hyperglycaemia model animals, db / db mice (8-week-old, 10 mice in total, average body weight 43.9 g) were purchased from Charles River Laboratories, Inc. and were domesticated for about one week before an experiment. A mixture obtained by blending sodium aspartate monohydrate and valine in a 5% carboxymethylcellulose solution using an agate mortar (sodium aspartate monohydrate 751 mmol / l, and valine 427 mmol / l) was administered orally using a feeding needle to five of the mice once a day on weekdays 10 a.m. to 11 a.m. (10 ml / kg, that is, sodium aspartate monohydrate 1.0 g / kg and valine 0.5 g / kg).

[0084]Only a solvent was administered orally to five of the control-administered group in the same manner as above. Administration was continued for two weeks, daily body weight measurement and blood collection immediately once a week before administration were performed to measure blood sugar levels in full feeding and concentrations of insulin-like growth factor I i...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Densityaaaaaaaaaa
Surface roughnessaaaaaaaaaa
Mass ratioaaaaaaaaaa
Login to view more

Abstract

The present invention provides a growth hormone secretion regulator or an anti-aging agent comprising aspartic acid and valine as active ingredients. The present invention also provides a pharmaceutical, food, nutritional supplement (supplement), or feeding stuff comprising the growth hormone secretion regulator or anti-aging agent.

Description

TECHNICAL FIELD[0001]The present invention relates to a growth hormone secretion regulator and anti-aging agent, and a pharmaceutical, food, nutritional supplement (supplement), or feeding stuff, which contain the growth hormone secretion regulator or anti-aging agent.BACKGROUND ART[0002]A growth hormone is a 22-kDa peptide hormone secreted from the pituitary gland. The growth hormone can provide various effects such as promotion of bone formation, increase in muscle mass, reduction in the amount of fat, thickening of skin, improvement of fertility, improvement of quality of life (QOL), or the like. Growth hormone is known to be secrete in a pulse-like manner, and it is elucidate that expression of the effects is largely affected by a secretion pattern of a growth hormone secreted in a pulse-like manner. Moreover, the amount of a growth hormone secreted is decreased with aging, and the secretion pattern is changed. As a result, the above-mentioned effects are reduced, resulting in c...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/197A61P3/00
CPCA23L1/3051A23V2002/00A61K8/347A61K8/44A61K31/198A61K2800/70A61Q19/08A61K2800/92A23V2200/302A23V2250/0654A23V2250/061A23L33/175A61P3/00A61P3/04A61P3/06A61P3/10A61P5/02A61P5/10A61P17/00A61P17/16A61P19/00A61P19/10A61P21/00A61P21/06A61P39/00A61P43/00
Inventor ONO, KAORIYONEZAWA, TOMOHIROMORI, MASATO
Owner AJINOMOTO CO INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products